Sonnet BioTherapeutics Holdings, Inc.
sonnetbio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2025 10-K, filed Dec 16, 2025. Its latest SEC filing is a 10-K/A from Jul 17, 2026.
10-K for FY2025, filed Dec 16, 2025
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Develops biologic drug candidates, mainly cytokine treatments for cancer, for use in patients with solid tumors and other diseases.
10-K for FY2025, filed Dec 16, 2025Sonnet BioTherapeutics Holdings, Inc. (“we,” “us,” “our,” or the “Company”), is a clinical stage, oncology-focused biotechnology company…View ↗
Our current internal pipeline development activities are focused on cytokines, a class of cell signaling proteins that, among other…View ↗
We have a pipeline of therapeutic compounds focused primarily on oncology indications of high unmet medical need.View ↗
Our lead proprietary asset, SON-1010, is a fully human single-chain version of Interleukin 12 (IL-12), covalently linked to the FHAB…View ↗
How Did They Make Money?
The company earns collaboration revenue from the combined Alkem license and trial supply when they are transferred; sales-based royalties are tied to related product sales. New Life collaboration revenue comes over the period its research and development work is performed.
10-K for FY2025, filed Dec 16, 2025
$1M
-
10-K for FY2025, filed Dec 17, 2025
$1M ↗
Who Were Their Customers?
Works with pharmaceutical partners on clinical studies and licenses drug candidates for development and commercialization. Alkem has rights to develop and commercialize SON-080 in India, while Roche supplies atezolizumab for a combination study.
10-K for FY2025, filed Dec 16, 2025
Did Revenues Turn Into Profits?
No. It lost $16M in FY2025.
10-K for FY2025, filed Dec 17, 2025
How Were They Changing?
Grew. Revenue grew 2.1x in 4 years, from $483.6K in FY2021 to $1M in FY2025, about 20% a year.
Discovery pipeline
The earlier report described an interleukin combination for melanoma and kidney cancers as a developing candidate; the latest report says a modified interleukin candidate replaces it, but that program is on hold.
10-K for FY2022, filed Dec 15, 2022SON-1410 (IL18-FHAB-IL12), a bispecific combination of Interleukins 18 (IL-18) and 12 (IL-12) for melanoma and renal cancers. Cell line…View ↗
Peripheral-neuropathy program
The earlier report described joint development with New Life and an ongoing Australian trial; the latest report describes an India license for Alkem, says the trial was terminated, and says New Life intends to return its rights.
10-K for FY2022, filed Dec 15, 2022 10-K for FY2025, filed Dec 16, 2025The Company acquired the global development rights to a fully human version of Interleukin 6 (“IL-6”), in April 2020. We refer to this…View ↗
We acquired the global development rights to a fully human version of Interleukin 6 (IL-6), in April 2020. We refer to this candidate as…View ↗
Pursuant to a license agreement (the “New Life Agreement”) we entered into with New Life Therapeutics Pte, Ltd. (“New Life”) of Singapore…View ↗
On October 8, 2024, we entered into the Alkem Agreement with Alkem. Pursuant to the Alkem Agreement, we granted Alkem an exclusive license…View ↗
Pancreatic cancer development
The earlier report described a solid-tumor candidate including colorectal cancer; the latest report also names pancreatic cancer and a clinical collaboration to test it with chemotherapy.
10-K for FY2022, filed Dec 15, 2022 10-K for FY2025, filed Dec 16, 2025SON-1210 (IL12-FHAB-IL15), our lead bispecific compound, combines the FHAB construct with fully human IL-12 and fully human Interleukin 15…View ↗
Who Did They Compete With?
Competes with Amgen, AstraZeneca/MedImmune, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, Kyorin Pharmaceuticals, Trevana, Eli Lilly, Ono Pharmaceuticals, Collegium Pharmaceuticals, Daiichi Sankyo, Avanir Pharmaceuticals, Vertex Pharmaceuticals, Applied Therapeutics, Helixsmith, Xilio Therapeutics, Werewolf Therapeutics, and Dragonfly Therapeutics
10-K for FY2025, filed Dec 16, 2025We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immuno-oncology treatments. There…View ↗
Loading...
